Patents Represented by Attorney Pamela C. Ancona

Find this attorney in the Justia Lawyer Directory

  • Benzamide inhibitors of the P2X7 Ereceptor
    Patent number: 6974812
    Abstract: The present invention provides benzamide inhibitors of the P2X7 receptor of the formula: wherein R1-R3 are as defined herein. The compounds of the invention are useful in the treatment of IL-1 mediated disorders, including, without limitation, inflammatory diseases such as osteoarthritis and rheumatoid arthritis; allergies, asthma, COPD, cancer, reperfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.
    Type: Grant
    Filed: December 30, 2003
    Date of Patent: December 13, 2005
    Assignee: Pfizer Inc.
    Inventors: Mark A Dombroski, Allen J. Duplantier
  • N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Patent number: 6919332
    Abstract: The present invention relates to N-substituted-heteroaryloxy-aryloxy-2,4,6-trione metalloproteinase inhibitors of the formula wherein X, A, Y, B, G, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: July 19, 2005
    Assignee: Pfizer Inc.
    Inventors: Mark C. Noe, Lilli Ann Wolf-Gouveia
  • Pyrimidinone fused bicyclic metalloproteinase inhibitors
    Patent number: 6828326
    Abstract: The present invention relates to fused bicyclic metalloproteinase inhibitors of the formula wherein A, B, X, Y, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating arthritis, inflammation, cancer and other disorders.
    Type: Grant
    Filed: August 5, 2003
    Date of Patent: December 7, 2004
    Assignee: Warner-Lambert Company
    Inventors: Joseph Armand Picard, Michael William Wilson
  • Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
    Patent number: 6509337
    Abstract: A compound of the formula wherein R1-R9 and Ar are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidemrolysis bullosa, scleritis and other disease characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases involving the production of TNF.
    Type: Grant
    Filed: September 17, 1998
    Date of Patent: January 21, 2003
    Assignee: Pfizer Inc.
    Inventors: Anthony Piscopio, James P. Rizzi